Market Size of North America Autoimmune Disease Diagnostics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 2.05 Billion |
Market Size (2029) | USD 2.68 Billion |
CAGR (2024 - 2029) | 5.53 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Autoimmune Disease Diagnostics Market Analysis
The North America Autoimmune Disease Diagnostics Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.68 billion by 2029, growing at a CAGR of 5.53% during the forecast period (2024-2029).
- The COVID-19 pandemic significantly impacted market growth, as there were increased complications of COVID-19 associated with various autoimmune diseases such as rheumatoid arthritis and type 1 diabetes, among others. For instance, according to an article published by the Lancet Discovery Science in January 2023, a study was conducted in the United States which showed COVID-19 infected patients had significantly higher risks of autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, dermatopolymyositis, and systemic sclerosis among others.
- Thus, the COVID-19 pandemic had a significant impact on the market during the initial phase; however, as the pandemic has subsided, the studied market is expected to have average growth during the forecast period of the study.
- The rising prevalence of autoimmune diseases and growing public awareness of autoimmune disorders is the primary factor driving the market growth. For instance, according to the data updated by the National Psoriasis Foundation of the United States in December 2022, it was estimated that more than 8 million Americans were living with psoriasis in the United States in 2021. An estimated 30% of people living with psoriasis are also expected to develop psoriatic arthritis, and the psoriasis prevalence in African Americans is estimated to be 1.5% compared to 3.6% in Caucasians.
- Thus, the high prevalence of autoimmune diseases such as psoriasis is expected to boost the adoption of autoimmune disease diagnostics. Furthermore, according to data updated by the Canadian Association of Psoriasis Patients in June 2021, psoriasis is considered a common, chronic, and disabling skin disease affecting about 1 million Canadians. Hence, the region's high prevalence of such autoimmune diseases is expected to boost the market growth.
- Moreover, increasing developments by major market players in the region are also expected to boost market growth, enabling patients to have diversified access to various products. For instance, in August 2021, the United States Food and Drug Administration (FDA) approved Thermo Fisher Scientific's blood test for diagnosing systemic lupus erythematosus (SLE) autoimmune disorder. The EliA SmDP-S test reduces the number of false-positive results and provides improved diagnostic guidance for the disease.
- Hence, the factors above, such as the high prevalence of autoimmune disorders such as psoriasis, among others, and the rising developments by major market players, are expected to boost the market growth. However, the slow turnaround time for autoimmune disease diagnostic test results and the high frequency of false positive results are expected to impede the market growth.